StemTech Of Malaysia Automates Adult Stem-Cell Harvesting
This article was originally published in PharmAsia News
Executive Summary
Malaysia's StemTech International became the first biotech in Southeast Asia to establish an automated processing technology system for harvesting adult stem cells and cord blood. The company said it had obtained the U.S.-made FACSCAlibur Cytometer for higher stem-cell yield, allowing for a higher survival rate in transplantation. The cytometer is capable of producing CD34 cell analysis and testing for cell viability. (Click here for more
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.